β¨ Medicines Notices
MARCH
NEW ZEALAND GAZETTE
Health
Medicines Act 1981
Corrigendum
Consent to the Distribution of New Medicines
In the notice published in the New Zealand Gazette, 15 December 1994, No. 135, page 4428, notice No. 9144, (i) for the word "methylprednisole" in the thirteenth line, replace the word "methylprednisolone"; and (ii) for the strength "50 mg/ml in 0.4 ml" in the fourteenth line, replace the strength "50 mg/ml in 0.8 ml". This in respect of the product Promedrol.
Dated this 28th day of February 1995.
DAVID SMYTH, Acting Director-General of Health, pursuant to the delegation given by the Minister of Health on the 25th day of June 1993.
oi649
Consent to the Distribution of Changed Medicines
Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Atracurium besylate 25 mg in 2.5 ml, 50 mg in 5 ml | Injection | Wellcome Foundation Limited, Temple Hill, Dartford, Kent, United Kingdom | Tracrium |
| Idarubicin 5 mg, 10 mg, 25 mg | Capsules | Pharmacia, Nerviano, Milan, Italy | Zavedos |
| Tenoxicam 20 mg, 40 mg | Powder for injection (glass vial and diluent) | F Hoffmann-La Roche Limited, Basle, Switzerland | Tilcotil |
| Glyceryl trinitrate 0.4 mg per spray | Oral metered spray | CCL Industries Limited, Runcorn, England and G Pohl Boskamp GmbH & Co., Hohenlockstedt, Germany | Nitrolingual pumpspray |
| Malathion 0.5% w/w | Liquid (topical) | Simco Limited, Vale, Guernsey, Channel Islands | Derbac-M |
| Cyclosporin A 25 mg, 50 mg, 100 mg Note: Not to be marketed as substitutable for Sandimmun as if the two (2) products were bioequivalent | Capsules | Sandoz Pharma Limited, Basle, Switzerland | Sandimmun-Neoral |
| Cyclosporin A 100 mg/ml in 20 ml and 50 ml Note: Not to be marketed as substitutable for Sandimmun as if the two (2) products were bioequivalent | Solution (oral) | Sandoz Pharma Limited, Basle, Switzerland | Sandimmun-Neoral |
| Simvastatin 5 mg, 10 mg, 20 mg and 40 mg | Tablets | Merck & Co Inc., Sumneytown Pike, West Point, Pennsylvania, United States of America and Merck Sharp & Dohme (Aust) Pty Limited, South Granville, New South Wales, Australia | Zocor |
| Pravastatin sodium 5 mg, 10 mg and 20 mg | Tablets | Bristol-Myers Squibb Pharmaceuticals Pty Limited, Noble Park, Victoria, Australia | Lipostat |
| Cefpodoxime proxetil 100 mg | Tablet | Roussel-Uclaf Usiphar Production Unit, Compeigne, France | Orelox |
| Interferon alpha-2a 3, 4.5, 6, 9 and 18 million IU | Powder for injection and diluent | F Hoffmann-La Roche Limited, Basle, Switzerland | Roferon-A |
Dated this 5th day of March 1995.
DAVID SMYTH, Acting Director-General of Health, pursuant to delegation given by the Minister of Health on 25 June 1993.
oi650
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1995, No 22
NZLII —
NZ Gazette 1995, No 22
β¨ LLM interpretation of page content
π₯ Corrigendum to Medicines Notice
π₯ Health & Social Welfare28 February 1995
Correction, Medicines Act, Promedrol, methylprednisolone
- DAVID SMYTH, Acting Director-General of Health
π₯ Consent to Distribution of Changed Medicines
π₯ Health & Social Welfare5 March 1995
Medicines Act, changed medicines, Tracrium, Zavedos, Tilcotil, Nitrolingual pumpspray, Derbac-M, Sandimmun-Neoral, Zocor, Lipostat, Orelox, Roferon-A
- DAVID SMYTH, Acting Director-General of Health
π₯ Consent to Distribution of New Medicines
π₯ Health & Social WelfareMedicines Act, new medicines